



A long noncoding RNA lincRNA EPS expression level in renal anemia in chronic kidney disease

LncRNA expression level in renal anemia

Veysel Berk Guner¹, Faruk Turgut¹, Huseyin Erdal², Serdar Dogan³

¹ Department of Nephrology, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Türkiye.

² Department of Medical Genetics, Faculty of Medicine, Aksaray University, Aksaray, Türkiye.

³ Department of Medical Biochemistry, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Türkiye.

This study was presented as an oral presentation at the 39th National Nephrology Congress, Antalya, Türkiye, 2024

Abstract

Aim: Chronic Kidney Disease (CKD) is a long-term medical condition characterized by the gradual loss of kidney function over time. Anemia is one of the most important causes of morbidity in patients with CKD. Anemia negatively affects the quality of life and mortality of patients and increases the progression of kidney disease. This is the first study to indicate lincRNA_EPS expression levels in CKD patients with renal anemia.

Methods: A total of 59 people were included in this study with 40 patients and 19 control groups. Analyses of lncRNA expression levels were performed by RT-qPCR method. Total RNA (including miRNA and lncRNA) was obtained from serum and plasma using an RNA isolation kit. Then, RNA concentration and purity were determined spectrophotometrically. The integrity of total RNA was determined by agarose gel electrophoresis.

Results: This study concluded that the lincRNA-EPS expression values were found to be significantly higher in the CKD group. There was no statistically significant correlation between the eGFR level of the patients and the lincRNA-EPS expression levels. However, a statistically significant positive correlation was found between eGFR values and hemoglobin levels in the patient group.

Conclusion: Considering the increased lincRNA-EPS expression level in CKD patients with renal anemia and its inverse correlation with EPO usage, a potential mechanism for facilitating erythropoiesis may involve both elevated lincRNA-EPS expression and suppression of the pro-apoptotic gene Pycard. Larger and more clinical studies are needed to fully elucidate the mechanism of action of the renal anemia-EPO/lincRNA-EPS relationship. In the light of these studies, it will be possible to identify new factors that play a role in the formation mechanisms of renal anemia and to evaluate new treatment alternatives.

Keywords

chronic kidney disease, renal anemia, erythropoietin, long non-coding RNA, lincRNA_EPS

DOI: 10.4328/ACAM.22218 Ann Clin Anal Med 2025;16(1):30-35

Received: 2024-04-10 Accepted: 2024-05-20 Published Online: 2024-11-04 Printed: 2025-01-01

Corresponding Author: Faruk Turgut, Department of Nephrology, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Türkiye.

E-mail: turgutfaruk@yahoo.com P: +90 505 642 17 12

Corresponding Author ORCID ID: <https://orcid.org/0000-0003-1910-7433>

Other Authors ORCID ID: Veysel Berk Guner, <https://orcid.org/0009-0003-2531-0988> . Huseyin Erdal, <https://orcid.org/0000-0003-0786-5077>
Serdar Dogan, <https://orcid.org/0000-0001-6854-2197>

Introduction

Chronic Kidney Disease (CKD) is a very common clinical entity with an irreversible, progressive and high cardiovascular risk secondary to changes in the function and/or structure of the kidney due to many reasons. CKD is an independent risk factor for cognitive dysfunction, hospitalization, and all-cause mortality.¹⁻³ CKD is very common in the general adult population and it is estimated to increase over time and reach a percentage of 13.1% among adults in the United State.⁴ Oxidative stress (OS) plays a significant role in the pathogenesis and progression of CKD. CKD is associated with increased production of reactive oxygen species (ROS) within the kidney. Various factors contribute to this, including inflammation, ischemia-reperfusion injury, mitochondrial dysfunction, and the activation of the renin-angiotensin-aldosterone system (RAAS). These ROS can damage cellular components such as lipids, proteins, and DNA leading to kidney injury and dysfunction.⁵⁻⁷ OS can directly damage red blood cells, making them more susceptible to premature destruction (hemolysis). This process reduces the lifespan of red blood cells and contributes to anemia by decreasing the total number of functional red blood cells in circulation. Numerous studies indicate that OS is a pivotal role in the development of several diseases.⁸⁻¹⁴

Anemia is a common complication of CKD and causes poor quality of life in patients with CKD. Although the mechanisms involved in the pathogenesis of renal anemia include chronic inflammation, iron deficiency, and shortening of the half-life of erythrocytes, the primary cause is relative erythropoietin deficiency. The American National Kidney Foundation Kidney Early Assessment Program has shown that the risk of anemia increases significantly when the glomerular filtration rate falls below 60 mL/min/1.73 m².¹⁵⁻¹⁶ The gene encoding human erythropoietin (EPO) is located on chromosome 7 and covers about 3,000 base pairs. It contains 5 exons and 4 introns and encodes a 193 amino acid polypeptide.¹⁷ Circulating EPO is mainly produced by peritubular fibroblast-like interstitial cells of the kidney.¹⁸ EPO is considered an important growth factor for late erythroid progenitor cells. Activation of EPO receptors on physiologically immature erythroid cells produces an intracellular signal that ensures the survival of these cells. The expected compensatory response to anemia is a high rate of erythropoiesis with an inverse ratio between hormone concentration and Hb concentration.¹⁹ Although chronic renal failure anemia is a complex disease in which many factors may play a role, the main defect is absolute or relative EPO deficiency. In most patients with substantially impaired renal function, EPO production is impaired at any hematocrit concentration independent of the level. The relative proportion of non-coding genomic DNA increases with developmental complexity, suggesting that ncRNAs served increasingly important biological functions during eukaryotic evolution. lncRNAs have come to the fore with newly defined roles in a wide variety of biological processes, including cell division, survival and differentiation.²⁰ The expression pattern of lncRNA genes has been shown to be much more tissue and cell type specific than for protein-coding genes.²¹ lncRNAEPS is minimally expressed in other hematopoietic lineages, it indicates erythroid specificity. In this study, the expression levels of a specific lncRNA (lincRNA-EPS) were examined in patients with CKD-related renal anemia and this lncRNA level was compared with a healthy control group. The relationship between this identified lncRNA (lincRNA-EPS) and anemia parameters is studied for the first time in humans. In the analysis of the results, if a significant relationship is shown between the determined lncRNAs and anemia parameters, it is aimed to determine new factors that play

a role in the pathophysiology of renal anemia and to evaluate new treatment alternatives.

LincRNA-EPS (one of the non-coding RNA family) was identified as a lincRNA that facilitates erythropoiesis by suppressing apoptosis via reducing the expression of the proapoptotic gene Pycard without altering erythroid differentiation.²² It is therefore important to determine how lincRNA-EPS represses Pycard and perhaps other proapoptotic targets. The most likely mechanism appears to be that lincRNA-EPS indirectly represses Pycard by inducing the synthesis of transcriptional repressors.²³

Materials and Methods

Study Groups

A total of 59 people were included in this study with 40 patients and 19 control groups. The inclusion criteria of study: Patients over 18 years of age, patients with stage 3-5 CKD and hemoglobin <10 g/dL, EPO-naïve or EPO-using patients; the exclusion criteria of study: Patients on hemodialysis or peritoneal dialysis, who have had a kidney transplant, with active infections, with known malignancy, have chronic liver disease, gastrointestinal bleeding, or other active bleeding conditions and the pregnant or breastfeeding women.

This study was conducted on patients with stage 3-5 CKD and hemoglobin value below 10 g/dL, who applied to Nephrology outpatient clinic of Hatay Mustafa Kemal University Training and Research Hospital between August 2021 and April 2022.

Sample Acquisition

Peripheral blood samples from chronic kidney patients and healthy controls were taken into tubes without and with anticoagulant (EDTA) (biochemistry tube with gel). After the blood samples taken into the biochemistry tube were coagulated at room temperature (20-30 minutes), they were centrifuged at 3500 rpm for 10 minutes + 4 °C to obtain serum. Serum samples were stored at -80 degrees until the day of study. The blood samples taken into the tube containing the anticoagulant were centrifuged at 3500 rpm for 10 minutes + 4 °C in the same way, and the plasma part was transferred to a separate microcentrifuge tube. These samples were also stored at -80 °C until analysis.

Gene Expression Analyzes

Analyzes of lncRNA expression levels were performed by RTqPCR method. Total RNA (including miRNA and lncRNA) was obtained from serum and plasma using an RNA isolation kit. Then, RNA concentration and purity were determined spectrophotometrically. The integrity of total RNA was determined by agarose gel electrophoresis. RNA samples with A260/A280 ratio between 1.8-2.0 were converted into cDNA using the cDNA synthesis kit. Real Time Quantitative Polymerase chain reaction (RT-qPCR) analyzes were performed on RotorGene device using SYBR Green master mix kit.

Primers associated with target genes were obtained from the manufacturer. lncRNA (lincRNA-EPS) gene expression analyzes were performed using primers. Analysis of gene expression data was done with QIAGEN's online program Data Analysis CenterRT2 Primer Assay. In the calculation of P values, the transcript was calculated based on 2-ΔΔCt values for each gene in the control and treatment groups, and p values below 0.05 were considered significant. GAPDH, β-actin and U6' were used as housekeeping genes in normalization.

Ethical Approval

This study was approved by the Ethics Committee of Hatay Mustafa Kemal University Clinical Research Ethics Committee (Date: 08.04.2021, Decision No: 2021/39).

Statistical Analysis

Statistical analysis was performed by Statistical Package for the Social Sciences (SPSS) 26 (SPSS Inc., Chicago, IL, USA) software. The collected data were calculated with appropriate descriptive statistics (mean, median, ratio, standard deviation, 95% confidence interval, etc.) methods. The conformity of the study data to the normal distribution was determined by the Shapiro-Wilk test. A comparison of data that did not show normal distribution was performed with the Mann-Whitney U test. P values less than 0.05 were considered significant. Spearman rank correlation was used because the data did not show normal distribution in the correlation analysis of the parameters. Results were expressed as mean ± standard deviation or median ± 25-75% percentile values ('interquartile range', IQ). 'SPSS 26' computer program was used for statistical analysis.

Reporting Guidelines

The study was reported in accordance with STROBE guidelines.

Results

This study consists of 59 people in total, 40 of whom are from the patient group and 19 from the healthy subjects.

Demographic characteristics, revealing minimal similarities between the patient and control groups are shown in Table 1. Females comprised 75.0% (30) and 52.6% (10) of the patient and control groups, respectively, while males constituted 25.0% (10) and 47.4% (9). Patients had a mean age of 64 ± 12 years, whereas the control group's mean age was 59 ± 9 years. Notably, body mass index, smoking, and blood pressures exhibited comparability between the two groups. As additional disease to CKD in the patient group: Isolated hypertension in 11 (27.5%) patients, hypertension, diabetes, hypertension and coronary artery disease in 9 (22.5%) patients, diabetes, hypertension and hyperlipidemia in 8 (20.0%) patients, diabetes and hypertension in 5 (12.5%) patients, coronary artery disease and hypertension in 4 (10.0%) patients, hyperlipidemia and hypertension in 2 (5.0%) and 1 patient has a

diagnosis of isolated diabetes (Figure 1). In the patient group; 17 (42.5%) patients with an eGFR value of 30-59 ml/min/1.73m² were evaluated as stage 3, 16 (40.0%) patients with an eGFR value of 15-29 ml/min/1.73m² as stage 4, 7 (17.5%) patients with eGFR <15 ml/min/1.73m² as stage 5 CKD.

The patients classified as stage 3 CKD, 9 (52.9%) hypertension and diabetes, 7 (41.1%) hypertension, 1 (6%) diabetes; the patients classified as stage 4 CKD, 11 (68.75%) hypertension and diabetes, 5 (31.25%) hypertension; the patients classified as stage 5 CKD, 5 (71.42%) hypertension, 2 (28.58%) hypertension and diabetes were the causes of kidney disease (Table 2). The distribution of EPO usage was 4 (23.52%) in stage 3 CKD patients, 5 (31.25%) in stage 4 CKD patients and 6 (85.71%) in stage 5 CKD patients. EPO usage doses in CKD patients according to stages were calculated as 50 mcg/week in stage 3 CKD patients, 46 mcg/week in stage 4 CKD patients, and 48.33mcg/week in stage 5 CKD patients (Table 2).

The laboratory values of all patients included in the study, the patients with CKD and the healthy control group are given in Table 3. Median and quartile lincRNA-EPS expression values in the healthy control group: The median value was 0.000041; 1st quartile (Q1): 0.000017, 2nd quartile (Q2): 0.000041, 3rd quartile (Q3): 0.00038; in the patient group: The median value was 0.5255; 1st quartile (Q1): 0.0072, 2nd quartile (Q2): 0.5255, 3rd quartile (Q3): 0.00038. Considering these data, lincRNA-EPS expression values were found to be significantly higher in the CKD group (p<0.001) (Figure 2). In the patient group, there was no statistically significant relationship between lincRNA-EPS expression levels in patients who received and did not receive EPO (p=0.106). There was no statistically significant correlation between lincRNA-EPS expression levels between diabetic and non-diabetic patients in the patient group (p=0.438).

Correlation Analysis Results

A statistically significant negative correlation was found between EPO levels and lincRNA-EPS expression levels in the between EPO levels and lincRNA-EPS expression levels in the patient group (r = -0.654, p=0.011) (Figure 3). There was no statistically significant

Table 1. Demographic characteristics and mean blood pressure values of the patients

Variable	Mean ± SD			
	Total (N = 59)	Patient (n = 40)	Control (n = 19)	P value
BMI (kg/m ²)	28.86 ± 4.03	28.31 ± 4.27	30.03 ± 3.30	.069
Smoking (%)	Yes	17 (28.8)	12 (30.0)	.772
	No	42 (71.2)	28 (70.0)	
Systolic blood pressure, mmHg	129.58 ± 14.15	131.50 ± 16.41	125.53 ± 5.98	.188
Diastolic blood pressure, mmHg	75.85 ± 4.03	75.50 ± 9.39	76.58 ± 7.08	0.444

Table 2. Causes of Patients' Kidney Disease and EPO Doses

Groups	Percent		
	CKD Stage 3 number n (%)	CKD Stage 4 number n (%)	CKD Stage 5 number n (%)
Kidney disease causes	HT: 7 (41.1)	HT: 5 (31.25)	HT: 5 (71.42)
	DM: 1 (6)	HT and DM: 11 (68.75)	HT and DM: 2 (28.58)
	HT and DM: 9 (52.9)		
EPO usage (Darbepoetin alfa) (mcg/w)	40-1 (6)	20-1 (6.25)	30 -1 (14.28)
	50-2 (11.7)	40-1 (6.25)	40-1 (14.28)
	60-1 (6)	50-1 (6.25)	50-2 (28.57)
		60-2(12.5)	60-2 (28.57)
Total N (%)	4 (23.52)	5 (31.25)	6 (85.71)
Averagedose used (mcg/w)	50	46	48.33

HT: Hypertension DM: Diabetes Mellitus EPO: Erythropoietin

Table 3. Laboratory Values of Total, Patient Group and Control Group

Variable	Mean ± SD or median value (min-max)			P value
	Total	Patient	Control	
WBC (10 ³ µ/L)	8.31 ± 2.92	8.99 ± 3.25	6.90 ± 1.19	.003
Hemoglobin (g/dL)	10.75 ± 2.52 (7.5-16.8)	9.14 ± 0.63 (7.5-9.9)	14.14±1.32 (12.1-16.8)	<0.001
MCV (fL)	85.13 ± 8.07	85.55 ± 877	84.25 ± 6.52	.501
Platelets (10 ³ µ/L)	261.39 ± 94.19	272.35 ± 101.25	238.32 ± 74.44	.212
BUN (mg/dL)	35.25 ± 19.75	44.67 ± 17.04	15.42 ± 3.88	<0.001
Creatinine (mg/dL)	1.92 ± 1.25	2.46±1.19	0.79 ± 0.14	<0.001
eGFH (ml/min/1.73m ²)	35.94 (7.0-104.21)	27.97 (7-59.89)	94.90 (72.41-104.21)	<0.001
Sodium (mmol/L)	138.02 ± 3.46	137.10 ± 3.51	139.5 ± 2.48	.004
Potassium (mmol/L)	4.58 ± 0.52	4.69 ± 0.57	4.37 ± 0.34	.010
Calcium (mg/dL)	9.24 ± 0.68	9.07 ± 0.74	9.62 ± 0.37	.002
Phosphorus (mg/dL)	3.97 ± 0.89	4.25 ± 0.91	3.40 ± 0.51	<0.001
PTH (pg/dL)	102.0 (16.7-845.0)	125.50 (16.7-845.0)	50.6 (18.3-174.0)	<0.001
ALP(U/L)	103.03 ± 53.91	111.53 ± 61.77	85.16 ± 24.48	.144
AST (U/L)	21.17 ± 9.76	21.35 ± 10.57	20.79 ± 8.06	.782
ALT (U/L)	18.19 ± 7.79	17.30 ± 7.78	20.05 ± 7.70	.146
Uric acid (mg/dL)	6.56 ± 2.33 (2.7-14.7)	7.13 ± 2.42 (2.7-14.7)	5.38±1.63 (2.9-10.1)	.005
Albumin(g/dL)	4.80 ± 0.57	3.82 ± 0.59	4.43 ± 0.24	<0.001
Ferritin(ng/mL)	63.50	74.75	37.50	.050
Vitamin B12 (Pg/MI)	506.81 ± 472.17	583.80 ± 556.12	344.74 ± 86.02	.330
Folate (ng/mL)	8.90 ± 4.15	7.75 ± 3.91	11.33 ± 3.63	<0.001
CRP (mg/L)	7.25 ± 5.24	8.14 ± 5.61	5.38 ± 3.83	.024
LincRNA-EPS expression	0.27 (0.10-0.99)	0.5255 (0.000017-12.99)	0.000041 (0.00000013-0.25)	<0.001

WBC: White Blood Cell Count, MCV: Mean Corpuscular Volume, BUN: Blood Urea Nitrogen, eGFR: Estimated Glomerular Filtration Rate, PTH: Parathormone, ALP: Alkaline Phosphatase, AST: Aspart Amino transferase, ALT: Alanine Amino transferase, CRP: C-Reactive Protein




Figure 1. Distribution of Additional Diseases to CKD in the Patient Group

DM: Diabetes Mellitus HT: Hypertension CAD: Coronary Artery Disease

correlation between the eGFR level of the patients and the lincRNA-EPS expression levels (p=0.897). Statistically significant positive correlation was found between eGFR values and hemoglobin levels in the patient group (r = 0.321, p=0.043). A statistically significant negative correlation was found between eGFR values and the

number of patients using EPO in the patient group (r = -0.432, p=0.005) and statistically significant positive correlation was found between the CKD stages of the patients and the number of patients using EPO (r = 0.377, p=0.016). In demographic data, no statistically significant correlation was found between age, BMI, and lincRNA-EPS expression levels in both the patient group and the healthy group (p=0.458, p=0.650 and p=0.580, p=0.814).

Discussion

This is the first report examining the lincRNA_EPS expression levels in CKD patients with renal anemia. We indicated the lincRNA-EPS expression values were found to be significantly higher in the CKD group (p<0.001). There was no statistically significant correlation between the eGFR level of the patients and the lincRNA-EPS expression levels (p=0.897). However, statistically significant positive correlation was found between




Figure 2. LincRNA-EPS Expression Levels in Patient and Control Groups




Figure 3. Negative Correlation Between EPO Levels and LincRNA-EPS Expression Levels in the Patient Group

eGFR values and hemoglobin levels in the patient group ($r = 0.321$, $p=0.043$). Moreover, in the patient group, there was no statistically significant relationship between lincRNA-EPS expression levels in patients who received and did not receive EPO ($p=0.106$). There was no statistically significant correlation between lincRNA-EPS expression levels between diabetic and non-diabetic patients in the patient group ($p=0.438$). The worldwide prevalence of CKD is estimated to be 8-16% and this number continues to rise.²² It is important to manage complications related to pathologies such as anemia, mineral and bone disorders, hydroelectrolytic disorders, metabolic acidosis and cardiovascular disease in patients diagnosed with CKD.²³

Studies have found an increased risk of developing or deepening anemia in correlation with the increase in CKD stage and the decrease in eGFR. In addition, evaluation of the patients after 5 years of follow-up studies data showed that CKD patients with anemia at baseline had a greater loss of renal function and a greater increase in all cardiovascular risks (myocardial infarction, heart failure, stroke, or death).²⁴ In this study, a statistically significant positive correlation was shown between the decrease in eGFR and the decrease in hemoglobin levels. Increased apoptosis of RBC progenitors can be associated with a variety of anaemias, including inflammation and cancerrelated conditions. It is possible that pharmacological inhibition of proapoptotic signaling pathways may be clinically beneficial, especially since many of these anemias are resistant to EPO therapy.²⁵ We investigated whether there is a significant relationship and correlation between lincRNA-EPS expression levels, renal anemia and EPO usage in stage 3-5 CKD patients. This study is the first in the literature to analyze this relationship. Considering that most of the lncRNA studies are carried out in animal experiments, it is particular important because the data obtained human origin in this study.

As a result of our study, statistically significant increase was found in lncRNA-EPS expression in the CKD patient group compared to the healthy control group. In addition, it was observed that there was significant negative correlation between the amount of EPO usage and the expression of lincRNA-EPS in the correlation analysis performed within the patient group. As a result of these data we have obtained, it is possible to establish a link between renal anemia, lincRNA-EPS and EPO usage. In patients with CKD, renal anemia deepens as a result of the decrease in the amount and/or effect of EPO, which protects erythroid precursors from apoptosis, and accelerates the progression of erythroid precursors to apoptosis. Considering the increased lincRNA-EPS expression level and the inverse correlation between EPO usage and lincRNA-EPS expression level in CKD patients with renal anemia; in order to facilitate erythropoiesis, the increase in lincRNA-EPS expression level and suppression of Pycard which is a proapoptotic gene, seems to be a possible mechanism.

Limitations

The limitations of our study include the fact that our study is a single-center and cross-sectional study, making it difficult to determine any causal relationship, and the decrease in the number of patients who meet our study group criteria due to the Covid-19 outbreak.

Conclusion

In conclusion, larger and more clinical studies are needed to fully elucidate the mechanism of action of the renal anemiaEPO-lincRNA-EPS relationship revealed by us. In the light of these studies, it will be possible to identify new factors that play a role

in the formation mechanisms of renal anemia and to evaluate new treatment alternatives. In this way, it will be possible to prevent the emergence of many bad clinical conditions accompanying renal anemia such as increased cardiovascular risk, increased rate of renal function loss as well as clinical conditions directly caused by anemia such as low quality of life, increased transfusion need, early and with less cost.

Declarations

Animal and Human Rights Statement

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was waived due to the retrospective design of the study.

Data Availability

The datasets used and/or analyzed during the current study are not publicly available due to patient privacy reasons but are available from the corresponding author on reasonable request.

Conflict of Interest

The authors declare that there is no conflict of interest.

Funding

None.

Abbreviations

BMI: Body mass index
CKD: Chronic kidney disease
EPO: Erythropoietin
eGFR: Estimated glomerular filtration rate
IQR: Interquartile range
lncRNA: Long non-coding ma
lincRNA-EPS: Long intergenic non-coding rna erythroid prosurvival
RAAS: Renin-angiotensin-aldosterone system
ROS: Reactive oxygen species
RT-qPCR: Real-time quantitative polymerase chain reaction

References

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* 2002;39(1)(suppl 1):S1-S266.
2. Drawz P, Rahman M. Chronic kidney disease. *Ann Intern Med.* 2015;162(11):ITC1-ITC16. doi:10.7326/aitc201506020
3. Erdal H, Ozcan O, Turgut F, Neselioglu S, Erel O. Evaluation of dynamic thiol-disulfide balance and ischemia-modified albumin levels in patients with chronic kidney disease. *MKU Tip Derg.* 2022;13(47):237-242. doi:10.17944/mkutfd.947113
4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. *JAMA.* 2007;298(17):2038-2047. doi:10.1001/jama.298.17.2038
5. Erdal H, Turgut F. Thiol/disulfide homeostasis as a new oxidative stress marker in patients with Fabry disease. *J Investig Med.* 2023;71(8):865-870. doi:10.1177/10815589231191966
6. Genc SO, Erdal H. Effect of mode of delivery on neonatal oxidative stress and dynamic thiol-disulfide homeostasis. *J Int Med Res.* 2023;51(10):3000605231202145. doi:10.1177/03000605231202145
7. Demirtas MS, Kilicbay F, Erdal H, Tunc G. Oxidative stress levels and dynamic thiol-disulfide balance in preterm newborns with bronchopulmonary dysplasia. *Lab Med.* 2023;54(6):587-592. doi:10.1093/labmed/lmad010
8. Demirtas MS, Erdal H, Kilicbay F, Tunc G. Association between thiol-disulfide homeostasis and transient tachypnea of the newborn in late-preterm and term infants. *BMC Pediatr.* 2023;23(1):135. doi:10.1186/s12887-023-03936-z
9. Erdal H, Demirtas MS, Tuncer SC, Ozcan O. Thiol/disulfide homeostasis as a new oxidative stress marker in patients with neonatal transient tachypnea. *Ann Clin Anal Med.* 2023;14(3):208-211. doi:10.4328/acam.21457
10. Zinellu A, Sotgia S, Loriga G, et al. Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. *Amino Acids.* 2012;43(4):1499-1507. doi:10.1007/s00726-012-1223-0
11. Erdal H, Bekmezci M. Evaluation of dynamic thiol/disulfide homeostasis and ischemia-modified albumin levels in cord blood of newborns to patients with oxytocin-induced labor. *ASUJSHR.* 2022;3(2):193-202.
12. Erdal H, Gunaydin FE, Karaoglanoglu S. Oxidative stress in asthma. *ASUJSHR.* 2023;4(1):62-70.
13. Nader E, Romana M, Guillot N, et al. Association between nitric oxide, oxidative stress, eryptosis, red blood cell microparticles, and vascular function in sickle cell anemia. *Front Immunol.* 2020;11:551441. doi:10.3389/fimmu.2020.551441
14. Kassianides X, Allgar V, Macdougall IC, et al. Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial. *Sci Rep.* 2022;12(1):6853. doi:10.1038/s41598-022-10717-8
15. Fadaee SB, Beetham KS, Howden EJ, et al. Oxidative stress is associated with decreased heart rate variability in patients with chronic kidney disease. *Redox Rep.* 2017;22(5):197-204.

doi:10.1080/13510002.2016.1173326

16. Whaley-Connell AT, Vassalotti JA, Collins AJ, et al. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2011: executive summary. *Am J Kidney Dis.* 2012;59(2)(suppl 2):S1-S4. doi:10.1053/j.ajkd.2011.11.018
17. Law ML, Cai GY, Lin FK, et al. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. *Proc Natl Acad Sci U S A.* 1986;83(18):6920-6924. doi:10.1073/pnas.83.18.6920
18. Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. *J Histochem Cytochem.* 1993;41(3):335-341. doi:10.1177/41.3.8429197
19. Caro J, Brown S, Miller O, et al. Erythropoietin levels in uremic nephric and anephric patients. *J Lab Clin Med.* 1979;93(3):449-458.
20. Mercer TR, Dinger ME, Sunkin SM, et al. Specific expression of long noncoding RNAs in the mouse brain. *Proc Natl Acad Sci U S A.* 2008;105(2):716-721. doi:10.1073/pnas.0706729105
21. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res.* 2012;22(9):1775-1789. doi:10.1101/gr.132159.111
22. Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature.* 2011;477(7364):295-300. doi:10.1038/nature10398
23. Paralkar VR, Weiss MJ. A new "linc" between noncoding RNAs and blood development. *Genes Dev.* 2011;25(24):2555-2558. doi:10.1101/gad.183020.111
24. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. *PLoS One.* 2014;9(1):e84943. doi:10.1371/journal.pone.0084943
25. Testa U. Apoptotic mechanisms in the control of erythropoiesis. *Leukemia.* 2004;18(7):1176-1199. doi:10.1038/sj.leu.2403383

How to Cite

Veysel Berk Guner, Faruk Turgut, Hüseyin Erdal, Serdar Doğan. A long noncoding RNA lincRNA EPS expression level in renal anemia in chronic kidney disease. *Ann Clin Anal Med* 2025;16(1):30-35. doi:10.4328/ACAM.22218